3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
19
Terminated
4
Unknown
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
42
Lung Neoplasms
13
Neoplasms
7
Brain Neoplasms
6
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
NSCLC
3
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Central Nervous System Neoplasms
2
Breast Neoplasms
2
Adenocarcinoma, Bronchiolo-Alveolar
2
Adenocarcinoma of Lung
2
Tongue Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Respiratory Tract Diseases
1
Relapsed Pediatric Solid Tumor
1
Recurrence
1
Precancerous Conditions
1
Optic Nerve Glioma
1
Non-squamous Non-small Cell Lung Cancer
1
Metastatic Pancreatic Adenocarcinoma
1
Medulloblastoma
1
Lung Diseases
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Familial ependymoma
1
Interventions
Cisplatin
28
Radiotherapy
20
pembrolizumab
9
Paclitaxel
9
Surveys and Questionnaires
8
Cetuximab
8
Fluorouracil
7
Docetaxel
7
Radiotherapy, Intensity-Modulated
6
Carboplatin
6
apatinib
5
Low-Level Light Therapy
5
Blood Specimen Collection
5
durvalumab
4
Standard of Care
4
Magnetic Resonance Imaging
4
Gemcitabine
4
Cyclophosphamide
4
Celecoxib
4
Tegafur
3
Radiation
3
Oncolytic Virotherapy
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Lidocaine
3
Immunoenzyme Techniques
3
Drug Therapy
3
Chemotherapy, Adjuvant
3
Biopsy
3
toripalimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Head and Neck Neoplasms
×
Erlotinib Hydrochloride
×
Clear all
NCT02748707
2022-04-28
ERLO-XIB
Tata Memorial Hospital
Phase 2
Unknown
64 enrolled